Neurocrine Biosciences (NBIX) Capital Expenditures Growth (3y) (2013 - 2026)

Neurocrine Biosciences (NBIX) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex Growth (3y) (Qtr)
1 Haleon 89.19 Bn 87.33 Bn - -
2 Teva Pharmaceutical Industries 35.86 Bn 32.12 Bn 1.97 Bn 6.52%
3 Zoetis 32.52 Bn 30.58 Bn 1.62 Bn 232.22%
4 Takeda Pharmaceutical 27.52 Bn 23.46 Bn 4.39 Bn 1.64%
5 United Therapeutics 23.22 Bn 21.07 Bn 648.10 Mn 75.58%
6 RedHill Biopharma 21.76 Bn 21.76 Bn - -
7 Viatris 20.29 Bn 18.48 Bn 1.16 Bn -5.84%
8 Neurocrine Biosciences 17.72 Bn 16.40 Bn 800.70 Mn 32.64%
9 Elanco Animal Health 12.59 Bn 12.16 Bn 785.00 Mn 28.56%
10 Vireo Growth 10.52 Bn 10.37 Bn 59.30 Mn 279.36%

Historic Data

Download Data
DateValue
Mar 31, 2026 32.64%
Dec 31, 2025 44.45%
Sep 30, 2025 35.72%
Jun 30, 2025 -66.69%
Mar 31, 2025 56.34%
Dec 31, 2024 61.37%
Sep 30, 2024 -30.12%
Jun 30, 2024 -79.28%
Mar 31, 2024 382.03%
Dec 31, 2023 -45.34%
Sep 30, 2023 -20.63%
Jun 30, 2023 25.99%
Mar 31, 2023 -9.14%
Dec 31, 2022 -8.70%
Sep 30, 2022 7.85%
Jun 30, 2022 -102.74%
Mar 31, 2022 67.11%
Dec 31, 2021 -27.13%
Sep 30, 2021 66.91%
Jun 30, 2021 -31.18%